Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin Window Trial in Invasive Breast Cancer
NCT03980509Phase 1Completed
- Sponsor
- Medical University of South Carolina
- Start
- Jan 2020
- Primary completion
- Mar 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of curcumin in breast cancer, sponsored by Medical University of South Carolina. Primary endpoint: Change in tumor proliferation rate (Ki67) up to 56 days. Started Jan 2020; status: completed.
02
Drugs
curcumin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03980509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980509.